Key technologies Alzheimer's clinical trials worldwide 2021

As of early 2021, 22 clinical trials for Alzheimer's disease used the β-amyloid mAb technology for a monoclonal antibody treatment. This statistic depicts the number of clinical trials for Alzheimer’s Disease products in the global pipeline as of 2021, by key technology.

Number of clinical trials for Alzheimer’s Disease products worldwide as of 2021, by key technology

Characteristic	Number of clinical trials
β-amyloid mAb	22
Combination treatment	8
Stem cells	7
Anti-tau mAb	7
Dopamine D₂ receptor partial agonist	6
Sigma1/2 receptor antagonist	6
Supplement/vitamin	6
SV2A protein modulator	5
ART	4
Vaccine	4
Cannabinoid	4
Other**	30

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

February 2021

More information

Region

Worldwide

Survey time period

as of February 2021

Number of respondents

109*

Supplementary notes

* Technologies with at least 2 clinical trials ongoing.
** Other includes various technologies each with <4 clinical trials, including: APP inhibitor, TKIs, Omega-3 fatty acid, NMDA receptor antagonist, α-2 adrenergic receptor agonist, AAV gene therapy, Nicotinamide riboside, 18-kDa TSPO radioligand, AChE inhibitor, QC inhibitor, Interleukin inhibitors, HGF stimulants, and undefined.

Citation formats